TLR3 BINDING AGENTS

摘要

The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

主权项

1. A method for treating or preventing a disease selected from the group consisting of autoimmunity, inflammation, allergy, asthma, infection, cirrhosis and sepsis, said method comprising administering to a patient in need thereof a therapeutically effective amount of an antibody that specifically binds a human Toll-like receptor 3 (TLR3) polypeptide, wherein said antibody inhibits signaling by said human TLR3 polypeptide without blocking binding of a double-stranded ribonucleic acid (dsRNA) TLR3 ligand to said human TLR3 polypeptide.